Fig. 1: High- and low-USP37 in SHH-driven MBs is associated with poor patient outcomes. | Oncogene

Fig. 1: High- and low-USP37 in SHH-driven MBs is associated with poor patient outcomes.

From: Identification of Raptor and GLI1 as USP37 substrates highlight its context-specific function in medulloblastoma cells

Fig. 1

A Human MB samples (n = 33) were stained with anti-USP37 antibodies and graded on a scale from (-) to (++++) based on the level of USP37 expression (magnification: 40×). B Quantitation of data shown in (A) to show the distribution of tumors with different grades and patterns of USP37 staining. C Graphical representation of data from (A) and (B) to show the inverse correlation between REST and USP37 levels. Each dot represents a tumor. Significance and correlation were measured using the unpaired t-test and Pearson correlation coefficient (r = 0.478 and P value = <0.0001). D USP37 gene expression in a microarray data set (GSE85217) [69] of human SHH- MB samples. Hierarchical clustering based on the expression of neuronal differentiation markers divided the SHH-type MB patient samples into six distinct clusters [48]. Each dot corresponds to an individual patient. Statistical significance was assessed using Welch’s t-test. E Kaplan–Meier plot to demonstrate significant differences in the overall survival of SHH-MB patients divided into four cohorts based on the relative expression of REST and USP37 in their tumors (GSE85217) [69]. Statistical significance between survival curves was assessed using the log-rank (Mantel–Cox) test. F Pathway analysis to show significantly enriched pathways in tumors with high-REST/low-USP37 expression relative to samples with low-REST/high-USP37 expression using the GSE124814 dataset [70].

Back to article page